NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...

NanoViricides, Inc. (NYSE American: NNVC) presented its latest advancements at the MicroCap <a target=_blank href= ...

NanoViricides, Inc. (NYSE American: NNVC) announced it has engaged a Clinical Research Organization (“CRO”) to conduct a Phase II clinical trial for ...

New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are ...

Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...

BENGALURU: Vaccines and antiviral, although not very effective are there for flu virus, however there are none which are clinically approved for mosquito borne ...

Antiviral drugs available for the prevention and treatment ... rapid and inexpensive tests are necessary for the development of a cost-effective test-treatment strategy for influenza.

Revolutionary Oral Interferon Technology Combines Unmatched Advantages and Global Potential in the $16 Billion Coronavirus Market SAN DIEGO, CA / ACCESS Newswire / January 27, 2025 / Ainos, Inc. (NASD ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Island Pharmaceuticals Ltd ( ($AU:ILA) ) has issued an announcement. Island Pharmaceuticals Ltd has progressed significantly in its ISLA-101 Phase ...